Ken Griffin Medicinova Inc Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.13 - $2.1 $2,485 - $4,620	2,200 Added 30.56%	9,400 $19,000
Q2 2024 Aug 14, 2024	SELL	$1.28 - $1.57 $6,784 - $8,321	-5,300 Reduced 42.4%	7,200 $10,000
Q1 2024 May 15, 2024	BUY	$1.28 - $1.65 $16,000 - $20,625	12,500 New	12,500 $18,000
Q2 2023 Aug 14, 2023	SELL	$2.09 - $2.43 $6,688 - $7,776	-3,200 Reduced 78.05%	900 $2,000
Q1 2023 May 15, 2023	SELL	$1.95 - $2.54 $23,400 - $30,480	-12,000 Reduced 74.53%	4,100 $8,000
Q4 2022 Feb 14, 2023	BUY	$1.97 - $2.66 $31,717 - $42,826	16,100 New	16,100 $33,000

4.83M

9.4K

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $89.8M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.